Dual-ligand-modified cantharidin nanoparticles demonstrated a 58.67% tumor inhibition rate in Huh-7 tumor-bearing mice, with enhanced safety profiles.

ClinicalJune 21, 2026

Innovative strategy combining cryoablation and immunotherapy for triple-negative breast cancer

The review proposes a multi-modal strategy using cryoablation and immunostimulants to enhance responses to immunotherapy in TNBC.

ClinicalJune 21, 2026

High-resolution multi-omics map of DLBCL reveals CD3+ B cell role in tumor microenvironment

The study provides insights into how neoplastic CD3+ B cells influence the DLBCL tumor microenvironment through advanced transcriptomic techniques.

RegulatoryJune 21, 2026

FDA Approves Supplemental Application for Capecitabine by Accord Healthcare

The FDA has approved a supplemental application for Capecitabine submitted by Accord Healthcare.

ClinicalJune 21, 2026

Phase 1 Study of Venetoclax Combination in T-Cell Acute Lymphoblastic Leukemia

A Phase 1 study is underway evaluating a combination of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab in adolescents and young adults with relapsed or refractory T-ALL or T-LBL.

RegulatoryJune 21, 2026

FDA Accepts Supplement for INQOVI by Taiho Oncology

The FDA has accepted a supplemental application for INQOVI (NDA212576) from Taiho Oncology.

StrategyJune 21, 2026

HPV-associated cancers impose significant burden on Peruvian men, highlighting need for vaccination and early diagnosis

HPV-associated cancers in Peruvian men resulted in 5,996 outpatient consultations and 1,136 hospitalizations from 2015-2019, with a significant number of deaths attributable to HPV.

RegulatoryJune 21, 2026

FDA Grants AP Status for Azacitidine ANDA204949 by Pharmobedient

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Azacitidine submitted by Pharmobedient.

RegulatoryJune 21, 2026

FDA Grants Approval for Gallium Ga-68 Gozetotide (ANDA216410)

The FDA has granted approval for the ANDA216410 application for Gallium Ga-68 Gozetotide submitted by Radiomedix.

ClinicalJune 21, 2026

Study on Gut Microbiota and Cachexia in Breast Cancer Patients Under Home Care

A study is evaluating the association between cancer cachexia and gut microbiota in breast cancer patients receiving home care, including the impact of a probiotic mixture.

ClinicalJune 21, 2026

Phase I/II Trial of Abemaciclib with Gemcitabine for Advanced Soft Tissue Sarcoma

A phase I/II trial is evaluating the safety and efficacy of abemaciclib combined with gemcitabine versus gemcitabine with docetaxel in patients with advanced soft tissue sarcoma.

ClinicalJune 21, 2026

Phase II/III Trial of Temozolomide With or Without Veliparib in Glioblastoma Multiforme

This trial is evaluating the efficacy of temozolomide combined with veliparib versus temozolomide alone in glioblastoma patients.

ClinicalJune 21, 2026

Alnylam's ALN-BCAT Study in Hepatocellular Carcinoma Evaluates Safety and Efficacy

Alnylam Pharmaceuticals is conducting a study to evaluate the safety and antitumor activity of ALN-BCAT, both alone and in combination with pembrolizumab, in patients with hepatocellular carcinoma.

ClinicalJune 21, 2026

Targeting Macrophage Cytokine Circuit Offers New Strategy Against TNBC Metastasis

Tumor-educated macrophages promote TNBC metastasis through a cytokine circuit, which can be disrupted pharmacologically.

ClinicalJune 21, 2026

Study Optimizes Immunotherapy for Pancreatic Adenocarcinoma Treatment

The study identifies opsonization and timing as critical factors influencing the efficacy of immunotherapy in pancreatic adenocarcinoma.

ClinicalJune 21, 2026

CircKPNA2 promotes colorectal cancer via RIN1-Ras pathway activation

CircKPNA2 is upregulated in colorectal cancer and activates the RIN1-Ras pathway, promoting tumor growth.

CompetitiveJune 21, 2026

Emerging Trends in CAR-T Immunotherapy Research for Breast Cancer Identified

A bibliometric analysis reveals significant research activity in CAR-T immunotherapy for breast cancer, highlighting key contributors and emerging hotspots.

ClinicalJune 21, 2026

Lactobacillus reuteri promotes ferroptosis resistance in esophageal cancer via STAT3 lactylation

Lactobacillus reuteri induces D-lactate production, promoting STAT3 lactylation and reducing ferroptosis in ESCC.

ClinicalJune 21, 2026

Novel KRAS(G12V)-targeting peptide shows potent activity against colorectal cancer cells

Peptide-1 demonstrated strong binding affinity to KRAS G12V and potent antiproliferative effects in colorectal cancer cell lines.

RegulatoryJune 21, 2026

FDA Accepts Supplemental Application for OPDUALAG by Bristol Myers Squibb

The FDA has accepted a supplemental application for OPDUALAG, a combination of nivolumab and relatlimab-rmbw.

ClinicalJune 21, 2026

NCI's MATCH Trial Evaluates Genetic Testing for Targeted Therapy in Advanced Cancers

The MATCH trial investigates the efficacy of treatment guided by genetic testing in patients with advanced refractory solid tumors, lymphomas, or multiple myeloma.

RegulatoryJune 20, 2026

FDA Accepts Supplement Application for DARZALEX by Janssen Biotech

The FDA has accepted the supplemental application for DARZALEX (daratumumab) from Janssen Biotech.

StrategyJune 20, 2026

FDA Grants Approval for Thalidomide ANDA213267 by NATCO

The FDA has granted approval for ANDA213267, a generic version of Thalidomide, submitted by NATCO.

ClinicalJune 20, 2026

Phase 1 Study of AMXT 1501 and DFMO for Neuroblastoma and CNS Tumors

A clinical trial is underway to evaluate the combination of AMXT 1501 and eflornithine (DFMO) for treating neuroblastoma and CNS tumors.

ClinicalJune 20, 2026

AbbVie initiates trial for telisotuzumab adizutecan in mCRC with FOLFOX and bevacizumab/panitumumab

A new study is evaluating the efficacy and safety of telisotuzumab adizutecan in combination with standard mCRC treatments.

ClinicalJune 20, 2026

Phase II/III Trial Compares Pre- and Post-Surgery Chemotherapy for Gallbladder Cancer

A phase II/III trial is underway to evaluate the efficacy of chemotherapy before and after surgery versus after surgery alone in stage II-III gallbladder cancer patients.

StrategyJune 20, 2026

HPV Vaccination Linked to Decline in High-Grade CIN Consultations in Brazil

The introduction of HPV vaccination in Brazil is associated with a significant decline in outpatient consultations for high-grade cervical intraepithelial neoplasia among adolescents.

ClinicalJune 20, 2026

Shikonin Induces Ferroptosis in DLBCL via lncRNA ADPGK-AS1 Downregulation

Shikonin suppresses DLBCL progression by inducing ferritinophagy and ferroptosis through lncRNA ADPGK-AS1 downregulation.

ClinicalJune 20, 2026

Phase II Trial of Lutetium Lu 177 Dotatate in Advanced Bronchial Neuroendocrine Tumors

A phase II trial is evaluating lutetium Lu 177 dotatate against everolimus for advanced bronchial neuroendocrine tumors.

ClinicalJune 20, 2026

Trial on Mobile Health Platform to Improve Adherence in Metastatic Breast Cancer Patients

A clinical trial is assessing the effectiveness of the CONCURxP platform in improving medication adherence among metastatic breast cancer patients on CDK4/6 inhibitors.

ClinicalJune 20, 2026

MITF-Driven Plasticity in Melanoma: Key to Overcoming Therapy Resistance

MITF-dependent phenotype switching is identified as a central mechanism enabling melanoma cells to escape therapy.

ClinicalJune 20, 2026

FCGR2B Targeting Enhances Anti-Tumor Activity of Macrophages in Melanoma

FCGR2B knockdown in tumor-associated macrophages enhances their anti-tumor capabilities by reducing M2 polarization and improving phagocytosis.

ClinicalJune 20, 2026

Systematic review on EGFR alterations in recurrent glioblastoma therapy response

The review assesses the predictive value of EGFR amplification and EGFRvIII mutation for EGFR-targeted therapy in recurrent glioblastoma.

ClinicalJune 20, 2026

RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization

RBMS1 enhances PDPK1 mRNA stability, promoting multiple myeloma cell proliferation and M2 macrophage polarization.

ClinicalJune 20, 2026

Role of GSH and H2S in Cancer Metabolism: Implications for Anticancer Strategies

Cancer cells produce higher levels of GSH and H2S, aiding their survival and drug resistance.

ClinicalJune 20, 2026

Study on Neuropsychological Changes in Brain Metastases Patients Undergoing Radiation Therapy

The study aims to evaluate cognitive and daily functioning changes in patients receiving radiation therapy for brain metastases.

ClinicalJune 20, 2026

Study on Cancer-related Fatigue in Chinese Cancer Patients Launched

An investigator-initiated study by Fudan University is assessing the incidence and severity of cancer-related fatigue in cancer patients.

ClinicalJune 20, 2026

Study on COVID-19 Vaccine Safety in Cancer Immunotherapy Patients Launched

A retrospective study is being initiated to evaluate the safety of COVID-19 vaccines in patients undergoing immunotherapy for cancer.

ClinicalJune 20, 2026

Study on Targeted Temperature Management to Reduce Delayed Neurocognitive Recovery in Elderly Cancer Patients

A clinical trial is investigating whether targeted temperature management during major cancer surgery can reduce delayed neurocognitive recovery in older patients.

ClinicalJune 20, 2026

Study Links Blood-Brain Barrier Disruption to Cognitive Impairment in Lung Cancer Patients

The study reveals a correlation between blood-brain barrier damage and cognitive impairment in untreated lung cancer patients.

ClinicalJune 20, 2026

High-Intensity Thermal Stress Boosts NK-Cell Cytotoxicity in HCC

High-intensity thermal stress enhances the cytotoxicity of NK-cells in poorly differentiated hepatocellular carcinoma.

ClinicalJune 20, 2026

MAGED4 promotes HCC progression via JAK2/STAT3 pathway activation

MAGED4 is upregulated in hepatocellular carcinoma and promotes tumor progression by activating the JAK2/STAT3 pathway.

ClinicalJune 20, 2026

CXCL13-expressing CD4(+) T cells enhance anti-tumor immunity in NSCLC through lymphocyte triad formation

CXCL13-expressing CD4(+) T cells recruit CXCR5(+) B cells, forming a triad with CD8(+) T cells that enhances anti-tumor immunity.

ClinicalJune 20, 2026

Lidocaine enhances efficacy of sorafenib and GW5074 in colorectal cancer cell lines

Lidocaine significantly enhances the antitumor effects of sorafenib and GW5074 in colorectal cancer cells, with varying responses across different cell lines.

StrategyJune 20, 2026

FDA Alerts Providers to Supply Disruption of Breast Biopsy Needles

The FDA has notified healthcare providers about a supply disruption affecting Stereotactic Breast Biopsy Needles.

RegulatoryJune 20, 2026

FDA Accepts Supplement Application for YERVOY (ipilimumab)

The FDA has accepted a supplemental application for YERVOY, an immune checkpoint inhibitor.

RegulatoryJune 20, 2026

FDA Grants Priority Review for Welireg Supplement from Merck

The FDA has granted priority review for the supplemental NDA for Welireg (belzutifan) submitted by Merck.

ClinicalJune 19, 2026

Gut Microbial Markers Linked to Immunotherapy Response in Melanoma Identified in Cross-Cohort Study

A cross-cohort analysis identified 527 metagenome-assembled genomes associated with immunotherapy response in melanoma patients, including specific bacterial species linked to treatment outcomes.

RegulatoryJune 19, 2026

FDA Accepts Supplemental Application for ALECENSA (Alectinib Hydrochloride)

The FDA has accepted a supplemental application for ALECENSA, indicating ongoing development and potential label expansion.

ClinicalJune 19, 2026

Study on Growth of Skin Neurofibromas in Neurofibromatosis Type 1 Initiated by NCI

The National Cancer Institute is conducting a study to investigate the growth patterns of dermal neurofibromas in patients with neurofibromatosis type 1.

ClinicalJune 19, 2026

Pentoxifylline and α-Tocopherol Study for RILI in Stage III NSCLC Patients

A clinical trial is investigating the efficacy of Pentoxifylline and α-Tocopherol in preventing radiation-induced lung injury in stage III NSCLC patients.

ClinicalJune 19, 2026

Advancements in NK Cell-Based Immunotherapy for Cancer Treatment

NK cell therapies are advancing with promising safety profiles and clinical applicability, leveraging various innovative strategies.

ClinicalJune 19, 2026

ULK1 Modulation Shows Promise in Cancer Therapy with DCC-3116 in Clinical Evaluation

DCC-3116, the first clinical agent targeting ULK1, shows on-target engagement and acceptable tolerability.

ClinicalJune 19, 2026

Phase II Trial of Venetoclax and HMA in FLT3 Mutated AML Patients

A phase II trial is comparing azacitidine and venetoclax to a combination of azacitidine, venetoclax, and gilteritinib in older patients with FLT3 mutated AML.

ClinicalJune 19, 2026

Tislelizumab and Zeprumetostat Show Promise in NK/T-Cell Lymphoma Phase Ib/II Trial

A phase Ib/II trial is evaluating the combination of tislelizumab and zeprumetostat in relapsed or refractory NK/T-cell lymphoma, focusing on determining the recommended phase II dose and assessing efficacy.

ClinicalJune 19, 2026

CRLX101 and Paclitaxel Combination Study in Ovarian Cancer Initiated by NewLink Genetics

A clinical trial is underway to evaluate the maximum tolerated dose of CRLX101 in combination with weekly paclitaxel for ovarian cancer patients.

ClinicalJune 19, 2026

NCI Launches Study on Natural History of CNS Tumors to Enhance Treatment Options

The National Cancer Institute is conducting a study to better understand brain and spinal cord tumors and improve treatment options.

CompetitiveJune 19, 2026

AstraZeneca Leads Study on DLBCL Treatment Patterns in MEA Region

AstraZeneca is sponsoring a multicenter observational study to analyze treatment patterns and access to novel therapies for DLBCL patients in the MEA region.

ClinicalJune 19, 2026

Amgen's Xaluritamig Plus Abiraterone Trial Targets Metastatic Prostate Cancer

Amgen is conducting a trial to compare overall survival in patients with metastatic castration-resistant prostate cancer receiving xaluritamig plus abiraterone versus standard treatments.

ClinicalJune 19, 2026

Phase II Trial of ILDR Plus Immunochemotherapy in Borderline Resectable Esophageal Cancer

A phase II trial is set to evaluate the efficacy and safety of intestinal low-dose radiotherapy combined with immunochemotherapy in patients with borderline resectable or unresectable esophageal squamous cell carcinoma.

ClinicalJune 19, 2026

Phase III Trial of Early Treatment in High-Risk CLL/SLL Shows Promise

The EVOLVE CLL/SLL study is comparing early versus delayed treatment with venetoclax and obinutuzumab in high-risk CLL/SLL patients.

ClinicalJune 19, 2026

Fruquintinib Study in Metastatic Colorectal Cancer Patients in Poland

A study is underway to evaluate the efficacy of fruquintinib in adults with metastatic colorectal cancer in Poland, focusing on progression-free survival and overall survival.

ClinicalJune 19, 2026

Phase 2 Study of Chidamide for MRD-Positive DLBCL in First Complete Remission

A phase 2 study is underway to assess chidamide maintenance therapy in adults with MRD-positive DLBCL post-complete response.

CompetitiveJune 18, 2026

First-in-human study of NTSR1-targeted imaging in prostate cancer shows promise

[18F]-AlF-NOTA-neurotensin shows potential as an NTSR1-targeted radiotracer for prostate cancer imaging.

ClinicalJune 18, 2026

Deciphera's Vimseltinib Study Evaluates Interaction with Oral Contraceptives

A clinical trial is underway to assess how vimseltinib affects the pharmacokinetics of a combined oral contraceptive.

ClinicalJune 18, 2026

St. Jude's Protocol for Long-term Review of Childhood Cancer Survivors

Jude Children's Research Hospital is implementing a protocol to monitor outcomes and late toxicity in childhood cancer patients.

ClinicalJune 18, 2026

Study on Frailty in Young Adult Survivors of Childhood Cancer Highlights Long-term Health Risks

A longitudinal study assesses frailty in young adult survivors of childhood cancer, revealing significant health risks.

RegulatoryJune 18, 2026

FDA Grants Priority Review for KEYTRUDA QLEX Supplement Application

The FDA has granted priority review for the supplemental application of KEYTRUDA QLEX, which includes pembrolizumab and berahyaluronidase alfa-PMPH.

RegulatoryJune 18, 2026

FDA Accepts Supplement Application for YERVOY (ipilimumab) by Bristol Myers Squibb

The FDA has accepted a supplemental application for YERVOY (ipilimumab) from Bristol Myers Squibb.

RegulatoryJune 18, 2026

FDA Acceptance of NDA for Capivasertib by AstraZeneca

The FDA has accepted the NDA for Capivasertib, indicating progress in its regulatory review.

RegulatoryJune 18, 2026

FDA Grants Priority Review for Welireg Supplement NDA215383

The FDA has granted priority review for the supplemental NDA for Welireg (belzutifan) submitted by Merck Sharp Dohme.

StrategyJune 18, 2026

Alembic submits ANDA for Bosutinib Monohydrate

Alembic has submitted an Abbreviated New Drug Application (ANDA) for Bosutinib Monohydrate.

ClinicalJune 18, 2026

Phase Ib/II Trial of QLC5508 and QLH12016 in Advanced Prostate Cancer

A Phase Ib/II clinical trial is underway to evaluate QLC5508 and QLH12016 in combination with other therapies for advanced prostate cancer.

ClinicalJune 18, 2026

Study Evaluates ePRO Follow-Up for Oncology Patients Post-Hospitalization

The study assesses the feasibility of using electronic patient-reported outcomes (ePRO) and transitional nurse consultations for oncology patients post-discharge.

ClinicalJune 18, 2026

Study on Treatment Patterns for Nivolumab in Community Oncology Settings

The study will analyze treatment patterns and safety events associated with nivolumab administration routes in cancer patients.

ClinicalJune 18, 2026

Phase II Trial of Proton Therapy for Craniopharyngioma Shows Feasibility and Safety

A Phase II trial is assessing the feasibility and safety of combining limited surgery with proton therapy for craniopharyngioma.

ClinicalJune 18, 2026

Study on De-escalation of Radiation Therapy in Node Negative Breast Cancer

A clinical trial is investigating the de-escalation of radiation therapy in women with clinically node negative breast cancer undergoing lumpectomy.

ClinicalJune 18, 2026

Phase II Trial of Olaparib and Durvalumab Combinations in Recurrent Endometrial Cancer

A phase II trial is evaluating the efficacy of combinations of olaparib, durvalumab, cediranib, and capivasertib in recurrent or refractory endometrial cancer.

ClinicalJune 18, 2026

Phase II Trial of Selumetinib and Olaparib in RAS Pathway Mutant Ovarian and Endometrial Cancers

A phase II trial is comparing the efficacy of selumetinib plus olaparib versus selumetinib alone in patients with RAS pathway mutant recurrent or persistent ovarian and endometrial cancers.

ClinicalJune 18, 2026

Phase II Trial of Nivolumab for Persistent Cervical Cancer Shows Potential Efficacy

A phase II trial is evaluating the efficacy and side effects of nivolumab in patients with persistent, recurrent, or metastatic cervical cancer.

ClinicalJune 18, 2026

RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer

The RAPTOR trial is assessing the efficacy of adding radiation therapy to atezolizumab maintenance in extensive stage small cell lung cancer.

ClinicalJune 18, 2026

ComboMATCH Trial Targets Genetic Mutations in Advanced Solid Tumors

The ComboMATCH trial aims to match patients with advanced solid tumors to targeted therapies based on genetic testing.

ClinicalJune 18, 2026

Nivolumab Phase III Trial for High Risk Stage II-IIIB Anal Cancer Initiated

A phase III trial is underway to evaluate the efficacy of nivolumab following combined modality therapy in high risk stage II-IIIB anal cancer patients.

ClinicalJune 18, 2026

Phase III Trial of Nivolumab Post-Surgery in Non-Small Cell Lung Cancer

A phase III trial is evaluating the efficacy of nivolumab following surgery and chemotherapy in patients with stage IB-IIIA non-small cell lung cancer.

ClinicalJune 18, 2026

Phase III Trial of Atezolizumab with Chemotherapy for Metastatic Colorectal Cancer Initiated

The COMMIT study is evaluating the efficacy of atezolizumab in combination with chemotherapy and bevacizumab for metastatic colorectal cancer with DNA mismatch repair deficiency.

ClinicalJune 18, 2026

Trial Comparing Radiotherapy with Dual Immunotherapy in Locally Advanced Rectal Cancer

A multicenter trial is evaluating the efficacy of different radiotherapy regimens combined with dual immunotherapy in LARC patients.

ClinicalJune 18, 2026

Phase III Trial Evaluates Pembrolizumab Timing in NSCLC Treatment

A phase III trial is comparing the efficacy of pembrolizumab alone versus in combination with chemotherapy as first-line treatment for stage IV non-squamous non-small cell lung cancer.

ClinicalJune 18, 2026

Phase III Trial of Pembrolizumab Plus Doxorubicin in Aggressive Sarcomas

A phase III trial is comparing immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) against chemotherapy alone in patients with metastatic or unresectable poorly differentiated sarcomas.

ClinicalJune 18, 2026

Sintilimab and Ipilimumab Show Promise in First-line Therapy for Advanced Biliary Tract Cancers

The combination of sintilimab and ipilimumab is being evaluated as a first-line therapy for unresectable and metastatic biliary tract cancers, addressing unmet needs in current treatment regimens.

ClinicalJune 18, 2026

Study on Educational Intervention for Breast Cancer Patients' Adherence and Sexual Function

This study evaluates the impact of an educational intervention on sexual function and treatment adherence in women with breast cancer.

ClinicalJune 18, 2026

Dabrafenib and Trametinib Rollover Study for Continued Patient Access

A rollover study has been initiated to provide continued access to dabrafenib and/or trametinib for patients benefiting from these treatments.

ClinicalJune 18, 2026

Cardiff Oncology and Pfizer assess onvansertib in metastatic colorectal cancer trial

A clinical trial is underway to evaluate onvansertib combined with standard therapies for first-line treatment of KRAS/NRAS-mutated metastatic colorectal cancer.

ClinicalJune 18, 2026

Study on ACS Geriatric Surgery Program's Impact on Older Cancer Patients

The study evaluates the implementation of the ACS GSV Program at James Cancer Hospital to enhance surgical outcomes for older adults.

ClinicalJune 18, 2026

Feasibility Study on Sensory Changes in Pediatric Oncology Patients Undergoing Treatment

The CANUT Junior study is assessing sensory changes in pediatric oncology patients, with initial recruitment challenges leading to protocol amendments.

ClinicalJune 17, 2026

ROBIN Trial to Explore RT Effects on Immune System in Rectal Cancer

The ROBIN trial will investigate the molecular effects of standard short course radiotherapy on rectal cancer and its impact on the immune system.

ClinicalJune 17, 2026

Study on Early Rehabilitation Protocol for Breast Cancer Surgery Shows Promising Safety and Feasibility

A new early rehabilitation protocol, EMOVE-BCS-LaFe, is being evaluated for safety and feasibility in breast cancer surgery patients.

ClinicalJune 17, 2026

SillaJen initiates Phase 1 trial of BAL0891 in advanced solid tumors and AML

SillaJen is conducting Phase 1 trial of BAL0891, evaluating its safety and tolerability in advanced solid tumors and relapsed/refractory AML.

ClinicalJune 17, 2026

Study on Durvalumab, Bevacizumab, and TACE for Advanced Hepatocellular Carcinoma

A clinical trial is evaluating the combination of durvalumab, bevacizumab, and TACE for advanced HCC, focusing on 6-month progression-free survival.

ClinicalJune 17, 2026

Zilovertamab Vedotin Shows Promise in rrDLBCL with Standard Care in Phase 2/3 Study

A Phase 2/3 study is evaluating zilovertamab vedotin in combination with standard care for rrDLBCL, with a protocol amendment discontinuing enrollment in one cohort.

RegulatoryJune 17, 2026

FDA Draft Guidance Aims to Reduce Animal Testing for Cancer Drugs

The FDA has issued draft guidance to minimize unnecessary animal testing in the development of cancer drugs.

RegulatoryJune 17, 2026

FDA Approves Supplement for INQOVI (NDA 212576) by Taiho Oncology

The FDA has approved a supplemental application for INQOVI, which contains the active ingredients cedazuridine and decitabine.

ClinicalJune 17, 2026

STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism

STARD10 is implicated in the progression of HER2+ breast cancer and regulates intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling pathway.

ClinicalJune 17, 2026

Phase 3 Trial of TQB2868 and Anlotinib in Metastatic Pancreatic Cancer Initiated

A randomized, open-label trial is underway to evaluate TQB2868 injection and anlotinib hydrochloride in combination with chemotherapy versus placebo.

ClinicalJune 17, 2026

DB-1303/BNT323 Trial in HER2-Low Metastatic Breast Cancer Initiated

A clinical trial is underway to evaluate DB-1303/BNT323 against investigator's choice chemotherapy in HER2-low, HR+ metastatic breast cancer.

ClinicalJune 17, 2026

Study on Exercise Program's Impact on Quality of Life in Prostate Cancer Patients

A clinical trial is assessing the effects of a structured exercise program on quality of life and health outcomes in prostate cancer patients.

ClinicalJune 17, 2026

Large Study on Breast Phyllodes Tumors in China Aims to Enhance Treatment Guidelines

A multi-center, retrospective study will analyze real-world data from 3,500 patients with breast phyllodes tumors in China.

ClinicalJune 17, 2026

Phase 2 Study of AUR103 Calcium in Advanced Neuroendocrine Tumours Initiated

AUR103 calcium is being evaluated in Phase 2 study for efficacy and safety in advanced neuroendocrine tumors.

ClinicalJune 17, 2026

Study Evaluates Outcomes After Discontinuation of BTK Inhibitors in CLL Patients

A Phase II study is assessing the outcomes of stopping BTK inhibitor therapy in CLL patients in remission for over two years.

ClinicalJune 17, 2026

Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis

Polyploid giant cancer cells (PGCCs) contribute to therapy resistance and poor prognosis in ovarian cancer.

ClinicalJune 17, 2026

Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

A novel lactylation-related prognostic model (CM-LP11) effectively stratifies cutaneous melanoma patients into high- and low-risk groups based on overall survival.

ClinicalJune 17, 2026

Gut Microbiota Impairs Flutamide Efficacy in Prostate Cancer Treatment

Gut bacteria metabolize Flutamide into inactive forms, reducing its therapeutic efficacy against prostate cancer.

ClinicalJune 17, 2026

Study Reveals Risk Factors for Second Primary Cancer in Colorectal Cancer Survivors

The study identifies age, neoadjuvant therapy, and tumor characteristics as risk factors for second primary cancer in colorectal cancer survivors.

ClinicalJune 17, 2026

Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma

Amplification of ARHGAP29 and SLC44A3 genes adjacent to F3 is associated with worse overall and disease-free survival in pancreatic adenocarcinoma.

ClinicalJune 17, 2026

E7 mRNA/LNP vaccine shows promise in treating early-stage HPV tumors in mice

The study demonstrates that the HPV16 E7 mRNA/LNP vaccine induces strong immune responses and tumor regression in early-stage HPV tumors in mice.

RegulatoryJune 17, 2026

Tebentafusp establishes first-line treatment for HLA-A*02:01-positive uveal melanoma

Tebentafusp (IMCgp100) significantly improved overall survival in HLA-A*02:01-positive advanced uveal melanoma, establishing it as a first-line treatment.

ClinicalJune 17, 2026

Study on Socio-aesthetics Care Impact on Cancer Patients' Quality of Life

A randomized controlled trial is evaluating the impact of socio-aesthetics well-being care on quality of life, pain, and anxiety in cancer patients.

ClinicalJune 17, 2026

Phase III Trial of Pembrolizumab with Chemotherapy in Non-small Cell Lung Cancer

The ALCHEMIST trial is evaluating the efficacy of adding pembrolizumab to standard chemotherapy in resected non-small cell lung cancer.

ClinicalJune 17, 2026

Phase 3 Trial of GammaTile vs Standard Care in GBM Surgery Initiated

A Phase 3 trial is underway comparing GammaTile implantation with standard care in patients undergoing GBM excision.

ClinicalJune 17, 2026

Phase III Trial Compares 6 vs. 12 Months of HER2-Targeted Therapy in Breast Cancer

A phase III trial is investigating whether 6 months of HER2-targeted therapy is more effective than 12 months for HER2-positive breast cancer patients who achieved a pathologic complete response after neoadjuvant chemotherapy.

ClinicalJune 17, 2026

Phase III Trial of Herceptin Hylecta or Phesgo with Chemotherapy for HER2 Positive Endometrial Cancer

A phase III trial is testing the efficacy of adding Herceptin Hylecta or Phesgo to standard chemotherapy in HER2 positive endometrial cancer.

ClinicalJune 17, 2026

Phase III Trial of MEDI5752 in Unresectable Pleural Mesothelioma Launched

A phase III trial is underway to evaluate the efficacy and safety of MEDI5752 in combination with standard chemotherapy in patients with unresectable pleural mesothelioma.

ClinicalJune 17, 2026

Phase III Trial of Giredestrant vs Endocrine Therapy in ER+ HER2- Early Breast Cancer

A Phase III trial is underway to evaluate giredestrant against standard endocrine therapy in ER-positive, HER2-negative early breast cancer.

RegulatoryJune 17, 2026

Ifinatamab Deruxtecan Receives Priority Review for ES-SCLC in the U.S.

Ifinatamab deruxtecan's Biologics License Application has been accepted and granted Priority Review by the FDA for ES-SCLC.

ClinicalJune 17, 2026

Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated

A Phase III trial is underway to evaluate the combination of durvalumab and domvanalimab in patients with unresectable NSCLC.

ClinicalJune 17, 2026

Phase III Trial Evaluates Cemiplimab with Surgery for Advanced Skin Cancer

A phase III trial is testing the addition of cemiplimab to standard surgery for resectable stage III/IV squamous cell skin cancer.

ClinicalJune 17, 2026

Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer

A phase III trial is comparing osimertinib alone versus its combination with bevacizumab in patients with EGFR-mutant non-small cell lung cancer.

ClinicalJune 17, 2026

Phase III Trial of SYHA1813 Shows Promise for High-Grade Meningiomas

A Phase III study is underway to evaluate SYHA1813 against investigator's choice treatment in high-grade meningioma patients.

ClinicalJune 17, 2026

Phase III Trial of Dinutuximab in High-Risk Neuroblastoma Shows Promise

A phase III trial is evaluating the efficacy of dinutuximab combined with standard chemotherapy and surgery for high-risk neuroblastoma in children.

StrategyJune 17, 2026

Merck's Acquisition of Terns Pharmaceuticals Advances as HSR Waiting Period Expires

Merck's acquisition of Terns Pharmaceuticals progresses as the HSR waiting period has expired, allowing the tender offer to move forward.

ClinicalJune 17, 2026

Trial Evaluates Pelvic Radiotherapy with ADT in Node Positive Prostate Cancer

A clinical trial is assessing the efficacy of adding pelvic radiotherapy to androgen deprivation therapy in patients with node-positive prostate cancer post-prostatectomy.

RegulatoryJune 17, 2026

FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment

The FDA has granted priority review for KEYTRUDA and KEYTRUDA QLEX in combination with Padcev for muscle-invasive bladder cancer.

ClinicalJune 17, 2026

Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC

The Phase 3 LITESPARK-012 trial did not meet its dual primary endpoints of progression-free survival and overall survival for the evaluated combination therapies.

StrategyJune 17, 2026

Roche Reports Strong Q1 2026 Sales Growth Driven by Innovative Medicines and Diagnostics

Roche's Q1 2026 sales grew 6% at constant exchange rates, driven by strong demand for innovative medicines, particularly in multiple sclerosis and oncology.

ClinicalJune 17, 2026

Phase III Trial of Durvalumab with Chemotherapy in Stage II-III Breast Cancer

A phase III trial is evaluating the addition of durvalumab to standard chemotherapy in patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

ClinicalJune 17, 2026

Phase III Trial Evaluates Hormone Therapy and Chemotherapy in Invasive Breast Cancer

A randomized phase III trial is assessing the efficacy of tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy in invasive breast cancer.

ClinicalJune 17, 2026

Phase III Trial Evaluates Triapine with Cisplatin for Advanced Cervical and Vaginal Cancers

A phase III trial is assessing the efficacy of adding triapine to standard cisplatin and radiation therapy for advanced-stage cervical and vaginal cancers.

ClinicalJune 17, 2026

Calderasib and Pembrolizumab Study in KRAS G12C NSCLC Shows Promising Efficacy

The study evaluates calderasib combined with pembrolizumab as a first-line treatment for KRAS G12C mutant NSCLC.

ClinicalJune 17, 2026

Phase II Trial Compares FOLFOX8 and mFOLFOX6 in Metastatic Colorectal Cancer

A phase II trial is underway to compare the efficacy and safety of FOLFOX8 versus mFOLFOX6 with bevacizumab or cetuximab in patients with unresectable metastatic colorectal cancer.

ClinicalJune 17, 2026

NeoAdjuvant Therapy Trial for TNBC: Sacituzumab Govitecan + Pembrolizumab

The ADAPT-TN-IV trial will explore the efficacy of Sacituzumab Govitecan combined with Pembrolizumab in neoadjuvant therapy for TNBC.

CompetitiveJune 17, 2026

Overview of Antibody-Drug Conjugates in Cancer Therapy and Clinical Development

Antibody-drug conjugates (ADCs) have shown significant clinical benefits in advanced phase trials for various cancers, with over a dozen receiving FDA approval.

StrategyJune 17, 2026

Merck Acquires Terns Pharmaceuticals, Enhancing Oncology Pipeline with TERN-701

Merck has completed the acquisition of Terns Pharmaceuticals, gaining TERN-701, a novel BCR::ABL1 inhibitor.

ClinicalJune 17, 2026

Pfizer's ELREXFIO Shows Significant PFS Improvement in RRMM Patients

The Phase 3 MagnetisMM-5 trial demonstrated a statistically significant improvement in progression-free survival for ELREXFIO in patients with relapsed or refractory multiple myeloma compared to standard-of-care.

RegulatoryJune 16, 2026

FDA Approves Bizengri for NRG1 Fusion-Positive Cholangiocarcinoma

The FDA has approved Bizengri (zenocutuzumab-zbco) for the treatment of NRG1 fusion-positive cholangiocarcinoma.

ClinicalJune 16, 2026

CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial

A Phase 2/3 study is evaluating CMP-001 in combination with nivolumab against nivolumab monotherapy in advanced melanoma.

RegulatoryJune 16, 2026

FDA ODAC Vote Against Camizestrant for HR-Positive Breast Cancer Raises Concerns

The FDA's ODAC did not reach a majority vote in favor of camizestrant's benefit-risk profile for advanced HR-positive breast cancer.

StrategyJune 16, 2026

Merck Acknowledges Daiichi Sankyo's ADC Manufacturing Update

Merck has acknowledged Daiichi Sankyo's update regarding its manufacturing and supply plan for ADC products.

CompetitiveJune 16, 2026

Roche to Acquire PathAI for $750M to Enhance AI-Driven Diagnostics

Roche has entered into a definitive agreement to acquire PathAI for $750 million, enhancing its digital pathology capabilities.

StrategyJune 16, 2026

Roche to Acquire PathAI for $750M to Enhance AI-Driven Diagnostics

Roche has entered into a definitive merger agreement to acquire PathAI for $750 million, enhancing its digital pathology capabilities.

RegulatoryJune 16, 2026

FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC

Calderasib (MK-1084) received Breakthrough Therapy designation for first-line treatment of KRAS G12C-mutant NSCLC.

CompetitiveJune 16, 2026

Merck Reports Promising Long-Term Data for KEYTRUDA and Intismeran in Oncology at ASCO 2026

Five-year follow-up data from KEYNOTE-942 show the potential of intismeran autogene in combination with KEYTRUDA for high-risk melanoma. Additionally, KEYNOTE-522 results indicate a continued survival benefit for high-risk early-stage TNBC patients.

RegulatoryJune 16, 2026

FDA Extends Decision Date for AstraZeneca's Camizestrant in HR-positive Breast Cancer

The FDA has extended the PDUFA date for camizestrant to allow for additional data review related to its NDA.

RegulatoryJune 16, 2026

Truqap approved in US for PTEN-deficient metastatic prostate cancer

Truqap, a first-in-class AKT inhibitor, has been approved in the US for treating PTEN-deficient metastatic hormone-sensitive prostate cancer.

ClinicalJune 16, 2026

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

Intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death in high-risk melanoma patients.

ClinicalJune 16, 2026

Lilly's Retevmo shows 83% reduction in disease recurrence for early-stage RET fusion-positive lung cancer

Phase 3 LIBRETTO-432 results indicate an 83% reduction in the risk of disease recurrence or death with Retevmo as adjuvant therapy.

RegulatoryJune 16, 2026

Imfinzi Gains US Approval for Early Bladder Cancer with BCG Combination

Imfinzi has been approved in the US as the first immunotherapy combination for BCG-naïve, high-risk non-muscle-invasive bladder cancer, showing a 32% reduction in disease recurrence, progression, or death.

RegulatoryJune 16, 2026

Enhertu Gains FDA Approval for Two New HER2+ Early Breast Cancer Indications

Enhertu has received FDA approval for two new indications in HER2-positive early breast cancer, both before and after surgery.

RegulatoryJune 16, 2026

FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer

The FDA ODAC has recommended Truqap in combination with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer.

CompetitiveJune 16, 2026

Lilly to present Phase 3 study of Retevmo in RET fusion-positive NSCLC at ASCO 2026

The Phase 3 LIBRETTO-432 study of Retevmo as adjuvant therapy in RET fusion-positive NSCLC will be highlighted at ASCO 2026.

RegulatoryJune 16, 2026

Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer

Datroway is approved in the US as the first TROP2-directed antibody drug conjugate for 1st-line treatment of metastatic triple-negative breast cancer.

ClinicalJune 16, 2026

Imfinzi + EV shows significant survival benefits in muscle-invasive bladder cancer

The Phase III VOLGA trial demonstrated that perioperative Imfinzi plus neoadjuvant EV significantly improves event-free survival and shows a favorable trend in overall survival for muscle-invasive bladder cancer.

RegulatoryJune 16, 2026

Camizestrant Recommended for 1st-Line ER-Positive Breast Cancer in EU

Camizestrant, in combination with CDK4/6 inhibitor, has been recommended for approval in the EU for 1st-line advanced ER-positive breast cancer based on SERENA-6 trial results.

RegulatoryJune 16, 2026

Merck's KEYTRUDA Plus Padcev Receives Positive EU CHMP Opinion for Muscle-Invasive Bladder Cancer

The EU CHMP has issued a positive opinion for the combination of KEYTRUDA and Padcev as a treatment for cisplatin-ineligible muscle-invasive bladder cancer.

ClinicalJune 16, 2026

Merck's Sacituzumab Tirumotecan Shows OS and PFS Improvement in Endometrial Cancer Phase 3 Trial

The TroFuse-005 trial demonstrated that sacituzumab tirumotecan significantly improved overall survival and progression-free survival compared to chemotherapy in patients with advanced or recurrent endometrial cancer.

StrategyJune 16, 2026

Roche and Nurix Collaborate on BTK Degrader Bexobrutideg for B-cell Malignancies

Roche has entered a collaboration with Nurix Therapeutics to co-develop bexobrutideg, BTK degrader targeting B-cell malignancies, immunology, and neurology.

ClinicalJune 16, 2026

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC

The Phase 3 KEYNOTE-D46/EVOKE-03 study of Trodelvy and KEYTRUDA has been discontinued due to lack of statistically significant efficacy.

CompetitiveJune 16, 2026

Pfizer and Innovent Collaborate on 12 Early-Stage Oncology Programs

Pfizer and Innovent Biologics have entered a strategic collaboration to co-develop 12 early-stage cancer medicines, including antibody-drug conjugates.

ClinicalJune 16, 2026

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche will present new data from the lidERA and persevERA studies, indicating giredestrant's potential as a new standard of care in early and advanced ER-positive breast cancer.

ClinicalJune 16, 2026

Roche to Present Promising Giredestrant Data at ASCO 2026 for Early Breast Cancer

Roche will present new data from the lidERA and persevERA studies, highlighting giredestrant's potential as a new standard of care for ER-positive breast cancer.

ClinicalJune 16, 2026

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC

The seven-year analysis of the CROWN trial shows a 55% likelihood of remaining alive without disease progression for patients treated with LORBRENA, with median progression-free survival not reached.

ClinicalJune 16, 2026

TALZENNA Plus XTANDI Shows 52% rPFS Improvement in Metastatic Prostate Cancer

The Phase 3 TALAPRO-3 study demonstrated that TALZENNA plus XTANDI significantly improved radiographic progression-free survival (rPFS) by 52% in patients with HRR gene-altered metastatic prostate cancer.

RegulatoryJune 16, 2026

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

The FDA has accepted Roche's NDA for giredestrant, an oral SERD, under priority review based on phase III data showing a 30% reduction in invasive disease recurrence or death compared to standard therapy.

RegulatoryJune 16, 2026

FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer

The FDA has accepted Roche's NDA for giredestrant, showing a 30% reduction in invasive disease recurrence compared to standard therapy.

ClinicalJune 16, 2026

Pfizer’s BRAFTOVI Regimen Nearly Doubles Progression-Free Survival in mCRC

The Phase 3 BREAKWATER study showed BRAFTOVI combined with cetuximab and FOLFIRI nearly doubled median progression-free survival to 15.2 months compared to 8.3 months with the comparator.

ClinicalJune 15, 2026

Non-coding RNAs as regulators of aerobic glycolysis in pancreatic ductal adenocarcinoma

Non-coding RNAs play significant roles in regulating aerobic glycolysis in pancreatic ductal adenocarcinoma.

ClinicalJune 15, 2026

Novel CD2-targeted bispecific antibody enhances T cell engagers for solid tumors

A novel CD2-targeted bispecific antibody combined with CD3 T cell engager shows improved efficacy and reduced toxicity in solid tumors.

ClinicalJune 15, 2026

Phase III Trial of TR115 vs Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma

A Phase III trial is underway to evaluate TR115, an EZH2 inhibitor, against standard treatments in relapsed/refractory peripheral T/NK-cell lymphoma.

ClinicalJune 14, 2026

New Biobank Established for Cutaneous Melanoma and Non-Melanoma Research

A new clinical trial is set up to create a biobank of human body material and clinical data from melanoma and non-melanoma patients.

RegulatoryJune 13, 2026

FDA Approves KEYTRUDA Combinations for Adjuvant Treatment in Clear Cell RCC

The FDA has approved KEYTRUDA and KEYTRUDA QLEX in combination with WELIREG for adjuvant treatment in ccRCC patients, marking a significant advancement in therapy.

RegulatoryJune 13, 2026

Roche's VENTANA PTEN Assay Receives FDA Approval for Prostate Cancer Companion Diagnostic

Roche's VENTANA PTEN (SP218) RxDx Assay is the first FDA-approved companion diagnostic for assessing PTEN protein loss in prostate cancer.

ClinicalJune 13, 2026

Trial on MRI-guided SBRT for Liver Metastases Aims to Establish Safe Dose Levels

A clinical trial is underway to determine the maximum tolerated dose of MRI-guided SBRT for liver metastases.

ClinicalJune 12, 2026

MRI-Guided Radiotherapy Trial for HPV Positive Oropharyngeal Cancer Initiated

A clinical trial is underway to compare MRI-guided IMRT dosing against standard IMRT in HPV positive oropharyngeal cancer patients.

ClinicalJune 12, 2026

Surufatinib trial initiated for adjuvant therapy in pancreatic neuroendocrine tumors

A randomized trial is underway to evaluate surufatinib as adjuvant therapy for pancreatic neuroendocrine tumors.

ClinicalJune 12, 2026

Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma

A first-in-human phase I/IIa trial is evaluating the safety and efficacy of [212Pb]VMT01, an alpha-particle therapy, in combination with nivolumab for advanced melanoma.

RegulatoryJune 11, 2026

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer

The FDA has accepted Roche's sBLA for Tecentriq plus chemotherapy in stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.

RegulatoryJune 11, 2026

FDA grants Priority Review for Roche’s Tecentriq in stage III colon cancer

The FDA has accepted Roche's sBLA for Tecentriq in combination with chemotherapy for stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.

ClinicalJune 11, 2026

Study on Image-Guided Cancer Treatments Using Spectral Angio-CT

A registry study is collecting data on minimally invasive cancer treatments using spectral angio-CT guidance in the Netherlands and France.

ClinicalJune 10, 2026

Phase II Trial of Venetoclax and Rituximab in Older Patients With Mantle Cell Lymphoma

A Phase II trial is underway to evaluate the efficacy of venetoclax combined with rituximab in older patients with untreated mantle cell lymphoma.

RegulatoryJune 7, 2026

FDA Grants AP Status for MESNA ANDA203364 Submission by RISING

The FDA has granted an Abbreviated Approval (AP) status for the MESNA ANDA203364 submission from RISING.

RegulatoryJune 6, 2026

FDA Submission Update for Ondansetron Hydrochloride (ANDA078127)

The FDA has received a supplemental application (ANDA078127) for Ondansetron Hydrochloride from PHARM ASSOC.

ClinicalJune 2, 2026

Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial

The EMERALD-3 Phase III trial demonstrated a statistically significant improvement in progression-free survival for Imfinzi plus Imjudo in patients with unresectable liver cancer.

ClinicalJune 2, 2026